The Health Resources and Services Administration today delayed to May 22 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers, and invited comments on whether a delay to Oct. 1 would be more appropriate. The rule was set to take effect March 21 following an earlier two-week delay. “[The Department of Health and Human Services] believes that the delay of the effective date is necessary to consider questions of fact, law and policy raised in the rule, consistent with the ‘Regulatory Freeze Pending Review’ memorandum,” the notice states. “In addition, HHS believes that the delay of the effective date is necessary to provide regulated entities sufficient time to implement the requirements of the rule.” HRSA will accept comments through April 17.

Related News Articles

Headline
The Centers for Medicare…
Blog
AHA staff recently visited two rural hospitals to see and hear firsthand how leaders are engaging in innovative practices to increase accessibility and…
Headline
The Centers for Medicare…
Headline
Tax-exempt hospitals in the 340B drug savings program provided $56.1 billion in total benefits to their communities in 2016, the most recent year for which…
Headline
The Centers for Medicare…
Headline
The Fund for Access to Inpatient Rehabilitation late yesterday announced that the government will settle backlogged Medicare inpatient rehabilitation facility…